Anabolic steroid detailed information
WikiDoc Resources for Anabolic steroid detailed information
Evidence Based Medicine
Guidelines / Policies / Govt
Patient Resources / Community
Healthcare Provider Resources
Continuing Medical Education (CME)
Experimental / Informatics
Anabolic steroids, also known as anabolic-androgenic steroids or AAS, are a class of steroid hormones related to the hormone testosterone. They increase protein synthesis within cells, which results in the buildup of cellular tissue (anabolism), especially in muscles. Anabolic steroids also have androgenic and virilizing properties, including the development and maintenance of masculine characteristics such as the growth of the vocal cords and body hair. The word anabolic comes from the Greek: anabole, "to build up", and the word androgenic comes from the Greek: andros, "man" + genein, "to produce".
Anabolic steroids were first isolated, identified and synthesized in the 1930s, and are now used therapeutically in medicine to stimulate bone growth and appetite, induce male puberty, and treat chronic wasting conditions, such as cancer and AIDS. Anabolic steroids also produce increases in muscle mass and physical strength, and are consequently used in sport and bodybuilding to enhance strength or physique. Serious health risks can be produced by long-term use or excessive doses of anabolic steroids. These effects include harmful changes in cholesterol levels (increased bad cholesterol and decreased good cholesterol), acne, high blood pressure, liver damage, and dangerous changes in the structure of the left ventricle of the heart. Some of these effects can be mitigated by exercise, or by taking supplemental drugs.
Performance enhancing substances have been used for thousands of years in traditional medicine by societies around the world, with the aim of promoting vitality and strength. In particular, the use of steroid hormones pre-dates their identification and isolation: medical use of testicle extract began in the late 19th century, and its effects on strength were also studied then. In 1889, the 72-year-old British neurologist Charles-Édouard Brown-Séquard injected himself with an extract of dog and guinea pig testicles, and reported at a scientific meeting that these injections had led to a variety of beneficial effects.
The development of modern pharmaceutical anabolic steroids can be traced back to 1931 when Adolf Butenandt, a chemist in Marburg, obtained 15 milligrams of the male hormone androstenone from tens of thousands of liters of urine. This hormone was synthesized in 1934 by Leopold Ruzicka, a chemist in Zurich. It was already known that the testes contained a more powerful androgen than androstenone, and three groups of scientists, funded by competing pharmaceutical companies in The Netherlands, Germany, and Switzerland, raced to isolate it.
This testicular hormone was first identified by Karoly Gyula David, E. Dingemanse, J. Freud and Ernst Laqueur in a May 1935 paper "On Crystalline Male Hormone from Testicles (Testosterone)." They named the hormone testosterone, from the stems of testicle and sterol, and the suffix of ketone. The chemical synthesis of testosterone was achieved in August that year, when Butenandt and G. Hanisch published a paper describing "A Method for Preparing Testosterone from Cholesterol." Only a week later, the third group, Ruzicka and A. Wettstein, announced a patent application in a paper "On the Artificial Preparation of the Testicular Hormone Testosterone (Androsten-3-one-17-ol)." Ruzicka and Butenandt were offered the 1939 Nobel Prize for Chemistry for their work, but the Nazi government forced Butenandt to decline the honor.
Clinical trials on humans, involving either oral doses of methyl testosterone or injections of testosterone propionate, began as early as 1937. Testosterone propionate is mentioned in a letter to the editor of Strength and Health magazine in 1938; this is the earliest known reference to an anabolic steroid in a U.S. weightlifting or bodybuilding magazine.
During the Second World War, German scientists synthesized other anabolic steroids, and experimented on concentration camp inmates and prisoners of war in an attempt to treat chronic wasting. They also experimented on German soldiers, hoping to increase their aggression. Adolf Hitler himself, according to his physician, was injected with testosterone derivatives to treat various ailments. The development of muscle-building properties of testosterone was pursued in the 1940s, in the Soviet Union and in Eastern Bloc countries such as East Germany, where steroid programs were used to enhance the performance of Olympic and amateur weight lifters. In response to the success of Russian weightlifters, the U.S. Olypmic Team physician worked with synthetic chemists to develop an anabolic steroid for American weightlifters, resulting in the production of methandrostenolone (Dianabol). Dianabol was approved for use in the U.S. by the Food and Drug Administration in 1958.
From the 1950s until the 1980s, there were doubts that anabolic steroids produced anything more than a placebo effect. In a 1972 study, participants were informed they would receive injections of anabolic steroids on a daily basis, but instead had actually been given a placebo. They reportedly could not tell the difference, and the perceived performance enhancement was similar to that of subjects taking the real anabolic compounds. According to Geraline Lin, a researcher for the National Institute on Drug Abuse, these results remained unchallenged for 18 years, even though the study used inconsistent controls and insignificant doses. In a 2001 study, the effects of high doses of anabolic steroids were examined, by injecting variable doses (up to 600 mg/week) of testosterone enanthate into muscle tissue for 20 weeks. The results showed a clear increase in muscle mass and decrease in fat mass associated with the testosterone doses.
Anabolic and androgenic effects
As the name suggests, anabolic-androgenic steroids have two different, but overlapping, types of effects. First, they are anabolic, meaning that they promote anabolism (cell growth). Some examples of the anabolic effects of these hormones are increased protein synthesis from amino acids, increased appetite, increased bone remodeling and growth, and stimulation of bone marrow, which increases the production of red blood cells.
Second, these steroids are androgenic or virilizing, meaning in particular that they affect the development and maintenance of masculine characteristics. The biochemical functions of androgens such as testosterone are numerous. Processes affected include pubertal growth, sebaceous gland oil production, and sexuality (especially in fetal development). Some examples of virilizing effects are growth of the clitoris in females and the penis in male children (the adult penis does not grow even when exposed to high doses of androgens), increased growth of androgen-sensitive hair (pubic, beard, chest, and limb hair), increased vocal cord size, deepening the voice, increased libido, suppression of natural sex hormones, and impaired production of sperm.
Through a combination of these effects, anabolic steroids stimulate the formation of muscles and hence cause an increase in the size of muscle fibers, leading to increased muscle mass and strength. This increase in muscle mass is mostly due to larger skeletal muscles, and is caused by both increased production of muscle proteins as well as a decline in the breakdown rate of these proteins. A high testosterone dose also decreases the amount of fat in muscle, while increasing protein content. Steroids also decrease overall fat.
Anabolic steroids can cause many adverse effects. Most of these side effects are dose-dependent, the most common being elevated blood pressure, especially in those with pre-existing hypertension, and harmful changes in cholesterol levels: some steroids cause an increase in bad cholesterol and a decrease in good cholesterol. Anabolic steroids such as testosterone also increase the risk of cardiovascular disease or coronary artery disease. Acne is fairly common among anabolic steroid users, mostly due to stimulation of the sebaceous glands by increased testosterone levels. Conversion of testosterone to dihydrotestosterone (DHT) can accelerate the rate of premature baldness for those who are genetically predisposed.
Other side effects can include alterations in the structure of the heart, such as enlargement and thickening of the left ventricle, which impairs its contraction and relaxation. Possible effects of these alterations in the heart are hypertension, cardiac arrhythmias, congestive heart failure, heart attacks, and sudden cardiac death. These changes are also seen in non-drug using athletes, but steroid use may accelerate this process. However, both the connection between changes in the structure of the left ventricle and decreased cardiac function, as well as the connection to steroid use have been disputed.
High doses of oral anabolic steroid compounds can cause liver damage as the steroids are metabolized (17α-alkylated) in the digestive system to increase their bioavailability and stability. When high doses of such steroids are used for long periods, the liver damage may be severe and lead to liver cancer.
There are also gender-specific side effects of anabolic steroids. Development of breast tissue in males, a condition called gynecomastia (which is usually caused by high levels of circulating estrogen), may arise because of increased conversion of testosterone to estrogen by the enzyme aromatase. Reduced sexual function and temporary infertility can also occur in males. Another male-specific side effect which can occur is testicular atrophy, caused by the suppression of natural testosterone levels, which inhibits production of sperm (most of the mass of the testes is developing sperm). This side effect is temporary: the size of the testicles usually returns to normal within a few weeks of discontinuing anabolic steroid use as normal production of sperm resumes. Female-specific side effects include increases in body hair, deepening of the voice, enlarged clitoris, and temporary decreases in menstrual cycles. When taken during pregnancy, anabolic steroids can affect fetal development by causing the development of male features in the female fetus and female features in the male fetus.
A number of severe side effects can occur if adolescents use anabolic steroids. For example, the steroids may prematurely stop the lengthening of bones (premature epiphyseal fusion through increased levels of estrogen metabolites), resulting in stunted growth. Other effects include, but are not limited to, accelerated bone maturation, increased frequency and duration of erections, and premature sexual development. Anabolic steroid use in adolescence is also correlated with poorer attitudes related to health.
Mechanism of action
The effect of anabolic steroids on muscle mass is caused in at least two ways: first, they increase the production of proteins; second, they reduce recovery time by blocking the effects of stress hormone cortisol on muscle tissue, so that catabolism of muscle is greatly reduced. It has been hypothesized that this reduction in muscle breakdown may occur through anabolic steroids inhibiting the action of other steroid hormones called glucocorticoids that promote the breakdown of muscles. Anabolic steroids also affect the number of cells that develop into fat-storage cells, by favouring cellular differentiation into muscle cells instead.
The main way in which steroid hormones interact with cells is by binding to proteins called steroid receptors. When steroids bind to these receptors, the proteins move into the cell nucleus and either alter the expression of genes or activate processes that send signals to other parts of the cell.
In the case of anabolic steroids, the receptors involved are called the androgen receptors. The mechanisms of action differ depending on the specific anabolic steroid. Different types of anabolic steroids bind to the androgen receptor with different affinities, depending on their chemical structure. Anabolic steroids such as methandrostenolone bind weakly to this receptor and instead directly affect protein synthesis or glycogenolysis. On the other hand, steroids such as oxandrolone bind tightly to the receptor and act mostly on gene expression.
Medical and non-medical uses
Since the discovery and synthesis of testosterone in the 1930s, anabolic steroids have been used by physicians for many purposes, with varying degrees of success.
- Bone marrow stimulation: For decades, anabolic steroids were the mainstay of therapy for hypoplastic anemias due to leukemia or kidney failure, especially aplastic anemia. Anabolic steroids have largely been replaced in this setting by synthetic protein hormones (such as epoetin alfa) that selectively stimulate growth of blood cell precursors.
- Growth stimulation: Anabolic steroids can be used by pediatric endocrinologists to treat children with growth failure. However, the availability of synthetic growth hormone, which has fewer side effects, makes this a secondary treatment.
- Stimulation of appetite and preservation and increase of muscle mass: Anabolic steroids have been given to people with chronic wasting conditions such as cancer and AIDS.
- Induction of male puberty: Androgens are given to many boys distressed about extreme delay of puberty. Testosterone is now nearly the only androgen used for this purpose and has been shown to increase height, weight, and fat-free mass in boys with delayed puberty.
- Testosterone enanthate has frequently been used as a male contraceptive and it is thought that in the near future it could be used as a safe, reliable, and reversible male contraceptive.
- Anabolic steroids have been found in some studies to increase lean body mass and prevent bone loss in elderly men. However, a 2006 placebo-controlled trial of low-dose testosterone supplementation in elderly men with low levels of testosterone found no benefit on body composition, physical performance, insulin sensitivity, or quality of life.
- Used in hormone replacement therapy for men with low levels of testosterone and is also effective in improving libido for elderly males.
- Used to treat gender dysmorphia (the belief that one was born the wrong gender) by producing secondary male characteristics, such as a deeper voice, increased bone and muscle mass, facial hair, increased levels of red blood cells and clitoral enlargement in female-to-male patients.
Non-medical use and abuse
It is difficult to determine what percent of the population in general have actually used anabolic steroids, but the number seems to be fairly low. Studies in the United States have shown anabolic steroid users tend to be mostly middle-class heterosexual men with a median age of about 25 who are noncompetitive bodybuilders and non-athletes and use the drugs for cosmetic purposes. According to a recent survey, 78.4% of steroid users were noncompetitive bodybuilders and non-athletes while about 13% reported unsafe injection practices such as reusing needles, sharing needles, and sharing multidose vials. Another study found that non medical use of AAS among college students was at or less than 1%. Most users do not compete in sports. Anabolic steroid users often are stereotyped as uneducated "muscle heads" by popular media and culture; however, a 1998 study on steroid users showed them to be the most educated drug users out of all users of controlled substances. Anabolic steroid users also tend to research the drugs they are taking more than any other group of users of controlled substances. Moreover, anabolic steroid users tend to be disillusioned by the portrayal of anabolic steroids as deadly in the media and in politics. According to one study, AAS users also distrust their physicians and in the sample 56% had not disclosed their AAS use to their physicians. A recent study has also shown that long term AAS users were more likely to have symptoms of muscle dysmorphia and also showed stronger endorsement of more conventional male roles.
Anabolic steroids have been used by men and women in many different kinds of professional sports (cricket, track and field, weightlifting, bodybuilding, shot put, cycling, baseball, wrestling, mixed martial arts, boxing, football, etc.) to attain a competitive edge or to assist in recovery from injury. Such use is prohibited by the rules of the governing bodies of many sports. Anabolic steroid use occurs among adolescents, especially by those participating in competitive sports. It has been suggested that the prevalence of use among high-school students in the U.S. may be as high as 2.7%. Male students used anabolic steroids more frequently than female students and, on average, those who participated in sports used steroids more often than those who did not.
There are three common forms in which anabolic steroids are administered: oral pills, injectable steroids, and skin patches. Oral administration is most convenient, but the steroid must be chemically modified so that the liver cannot break it down before it reaches the systemic circulation; these formulations can cause liver damage in high doses. Injectable steroids are typically administered into the muscle, not into the vein, to avoid sudden changes in the amount of the drug in the bloodstream. Transdermal patches (adhesive patches placed on the skin) may also be used to deliver a steady dose through the skin and into the bloodstream.
Minimization of side effects
Various methods of minimizing the adverse effects of anabolic steroids have been implemented by those using them either for medical or other reasons. For example, users may increase their cardiovascular exercise level to help to counter the effects of changes in the left ventricle. Some androgens are converted by the body into estrogen, a process, known as aromatisation, which has potential adverse effects described previously. Consequently, during a steroid cycle, users may also take drugs to prevent aromatisation (called aromatase inhibitors) or drugs which affect estrogen receptor binding (called selective estrogen receptor modulators or SERMs): for example, the SERM tamoxifen prevents binding to the estrogen receptor in the breast, and so it can be used to reduce the risk of gynecomastia.
To combat the natural testosterone suppression and to restore proper function of numerous glands involved, what is known as "post-cycle therapy" or PCT is sometimes used. PCT takes place after each cycle of anabolic steroid use and typically consists of a combination of the following drugs, depending on which protocol is used:
- A SERM such as clomiphene citrate or tamoxifen citrate (this is the primary PCT drug).
- An aromatase inhibitor such as anastrozole.
- Human chorionic gonadotropin, although it is more common now to use this throughout the cycle rather than after it.
The aim of PCT is to return the body's endogenous hormonal balance to its original state within the shortest period of time. People prone to the premature hair loss exacerbated by steroid use have been known to take the prescription drug finasteride for prolonged periods of time. Finasteride reduces the conversion of testosterone to DHT, the latter having much higher potency for alopecia. Finasteride is useless in the cases when steroid is not converted into a more androgenic derivative. Since anabolic steroids can be toxic to the liver or can cause increases in blood pressure or cholesterol, many users consider it ideal to get frequent blood work tests and blood pressure tests to make sure their blood pressure or cholesterol are still within normal levels.
Misconceptions and controversies
Anabolic steroids, like many other drugs, have generated much controversy. There are also many popular misconceptions concerning their effects and side effects. One common misconception in popular culture and the media is that anabolic steroids are highly dangerous and users' mortality rates are high. Anabolic steroids are used widely in medicine with an acceptable side-effect profile, so long as patients are monitored for possible complications. Former assistant professor at the University of Toronto and World Wrestling Entertainment athletic physician Mauro Di Pasquale has stated, "As used by most people, including athletes, the adverse effects of anabolic steroids appear to be minimal."
One of the earliest misconceptions concerning anabolic steroids revolve around claims that Lyle Alzado died from brain cancer caused by anabolic steroids. Indeed, Alzado himself claimed that anabolic steroids were the cause of his cancer. However, although steroids can cause liver cancer, there is no published evidence that anabolic steroids cause either brain cancer or the specific type of T-cell lymphoma that caused his death. Alzado's doctors stated that anabolic steroids did not contribute to his death.
Another example is the misconception that anabolic steroids can shrink the male penis. It is possible that this idea came from temporary side effect that anabolic steroids have on testicle size (testicular atrophy), discussed previously.
Other purported side effects include the idea that anabolic steroids have caused many teenagers to commit suicide. While lower levels of testosterone have been known to cause depression, and ending a steroid cycle temporarily lowers testosterone levels, the hypothesis that anabolic steroids are responsible for suicides among teenagers remains unproven. Although teen bodybuilders have been using steroids since at least the early 1960s, only a few cases suggesting a link between steroids and suicide have been reported in the medical literature.
Another condition that is frequently discussed as a possible side effect of anabolic steroids is known as "roid rage"; however there is no consensus in the medical literature as to whether such a condition actually exists. Testosterone levels are indeed associated with aggression and hypomania, but the link between other anabolic steroids and aggression remains unclear. While some studies have shown a correlation between manic symptoms and anabolic steroid use, later studies have questioned these conclusions. Currently, three blind studies have demonstrated a link between aggression and steroid use, but with estimates of over one million past or current steroid users in the United states, an extremely small percentage of those using steroids appear to have experienced mental disturbance severe enough to result in clinical treatments or medical case reports.  Individual studies vary in their findings, with some reporting no increase in aggression or hostility with anabolic steroid use, and others finding a correlation. Including a study of two pairs of identical twins, in which one twin used anabolic steroids and the other did not, found that in both cases the steroid-using twin exhibited high levels of aggressiveness, hostility, anxiety and paranoid ideation not found in the "control" twin.
It has previously been theorized that some studies showing a correlation between angry behavior and steroid use are confounded by the fact that steroid users are likely to demonstrate cluster B personality disorders prior to administering steroids. In addition, many case studies have concluded anabolic steroids have little or no real effect on increased aggressive behavior.
Arnold Schwarzenegger is the subject of an urban legend regarding the side effects of anabolic steroids. Schwarzenegger has admitted to using anabolic steroids during his bodybuilding career for many years prior to them being made illegal, and in 1997 he underwent surgery to correct a defect relating to his heart. Some have assumed this was due to anabolic steroids. Although anabolic steroid use can sometimes cause unfavorable enlargement and thickening of the left ventricle, Schwarzenegger was born with a congenital genetic defect in which his heart had a bicuspid aortic valve — in other words, whereas normal hearts have three cusps, his had only two, which can occasionally cause problems later in life.
- Grishkovskaya I, Avvakumov GV, Sklenar G, Dales D, Hammond GL, Muller YA (2000). "Crystal structure of human sex hormone-binding globulin: steroid transport by a laminin G-like domain". EMBO J. 19 (4): 504–12. doi:10.1093/emboj/19.4.504. PMID 10675319.
- "A short doping history". Anti-Doping Hotline. Retrieved 2007-04-24.
- Kuhn CM (2002). "Anabolic steroids". Recent Prog. Horm. Res. 57: 411–34. PMID 12017555.
- Hoberman JM, Yesalis CE (1995). "The history of synthetic testosterone". Sci. Am. 272 (2): 76–81. PMID 7817189.
- Hoberman JM, Yesalis CE (1995). "The history of synthetic testosterone". Scientific American. 272: 76&ndash, 81. PMID 7817189.
- Freeman ER, Bloom DA, McGuire EJ (2001). "A brief history of testosterone". Journal of Urology. 165: 371&ndash, 373. PMID 11176375.
- David K, Dingemanse E, Freud J, Laqueur L (1935). "Uber krystallinisches mannliches Hormon aus Hoden (Testosteron) wirksamer als aus harn oder aus Cholesterin bereitetes Androsteron". Hoppe Seylers Z Physiol Chem. 233: 281.
- Butenandt A, Hanisch G. (1935). "A Method for Preparing Testosterone from Cholesterol". Chemische Berichte. 68: 1859.
- Ruzicka L, Wettstein A (1935). "Sexualhormone VII. Uber die
kunstliche Herstellung des Testikelhormons. Testosteron (Androsten-3-one-17-ol.)". Helvetica Chimica Acta. 18: 1264. line feed character in
|title=at position 28 (help)
- Taylor, William N. (1991). Macho Medicine: A History of the Anabolic Steroid Epidemic. McFarland & Company. ISBN 978-0899506135.
- Sweitzer, Philip J. (2004). "Drug law enforcement in crisis: cops on steroids" (PDF). Journal of Sports Law and Contemporary Problems. 2 (2). Retrieved 2007-05-16.
- Calfee R, Fadale P (2006). "Popular ergogenic drugs and supplements in young athletes". Pediatrics. 117 (3): e577–89. doi:10.1542/peds.2005-1429. PMID 16510635.
- Medicine and Science in Sports, Anabolic steroids: the physiological effects of placebos. (Ariel & Saville, 1972).
- Lin, Geraline (1996). Anabolic Steroid Abuse ISBN 0-7881-2969-4
- Bhasin S, Woodhouse L, Casaburi R; et al. (2001). "Testosterone dose-response relationships in healthy young men". Am J Physiol Endocrinol Metab. 281 (6): E1172–81. PMID 11701431.
- "Recent Progress in Hormone Research - Anabolic steroids". The Endocrine Society. Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina (57): 411–434. 2002.
- Schroeder E, Vallejo A, Zheng L; et al. (2005). "Six-week improvements in muscle mass and strength during androgen therapy in older men". J Gerontol A Biol Sci Med Sci. 60 (12): 1586–92. PMID 16424293.
- Grunfeld C, Kotler D, Dobs A, Glesby M, Bhasin S (2006). "Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study". J Acquir Immune Defic Syndr. 41 (3): 304–14. PMID 16540931.
- Giorgi A, Weatherby R, Murphy P (1999). "Muscular strength, body composition and health responses to the use of testosterone enanthate: a double blind study". Journal of science and medicine in sport / Sports Medicine Australia. 2 (4): 341–55. PMID 10710012.
- Grace F, Sculthorpe N, Baker J, Davies B (2003). "Blood pressure and rate pressure product response in males using high-dose anabolic-androgenic steroids (AAS)". J Sci Med Sport. 6 (3): 307–12. PMID 14609147.
- Tokar, Steve (2006 Feb). "Liver Damage And Increased Heart Attack Risk Caused By Anabolic Steroid Use". University of California - San Francisco. Retrieved 2007-04-24. Check date values in:
- Barrett-Connor E (1995). "Testosterone and risk factors for cardiovascular disease in men". Diabete Metab. 21 (3): 156–61. PMID 7556805.
- Bagatell C, Knopp R, Vale W, Rivier J, Bremner W (1992). "Physiologic testosterone levels in normal men suppress high-density lipoprotein cholesterol levels". Ann Intern Med. 116 (12 Pt 1): 967–73. PMID 1586105.
- Mewis C, Spyridopoulos I, Kühlkamp V, Seipel L (1996). "Manifestation of severe coronary heart disease after anabolic drug abuse". Clinical cardiology. 19 (2): 153–5. PMID 8821428.
- Hartgens F, Kuipers H (2004). "Effects of androgenic-anabolic steroids in athletes". Sports Med. 34 (8): 513–54. PMID 15248788.
- Melnik B, Jansen T, Grabbe S (2007). "Abuse of anabolic-androgenic steroids and bodybuilding acne: an underestimated health problem". Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 5 (2): 110–7. doi:10.1111/j.1610-0387.2007.06176.x. PMID 17274777.
- De Piccoli B, Giada F, Benettin A, Sartori F, Piccolo E (1991). "Anabolic steroid use in body builders: an echocardiographic study of left ventricle morphology and function". Int J Sports Med. 12 (4): 408–12. PMID 1917226.
- Sullivan ML, Martinez CM, Gallagher EJ (1999). "Atrial fibrillation and anabolic steroids". The Journal of emergency medicine. 17 (5): 851–7. PMID 10499702.
- Dickerman RD, Schaller F, McConathy WJ (1998). "Left ventricular wall thickening does occur in elite power athletes with or without anabolic steroid Use". Cardiology. 90 (2): 145–8. PMID 9778553.
- George KP, Wolfe LA, Burggraf GW (1991). "The 'athletic heart syndrome'. A critical review". Sports medicine (Auckland, N.Z.). 11 (5): 300–30. PMID 1829849.
- Dickerman R, Schaller F, Zachariah N, McConathy W (1997). "Left ventricular size and function in elite bodybuilders using anabolic steroids". Clin J Sport Med. 7 (2): 90–3. PMID 9113423.
- Salke RC, Rowland TW, Burke EJ (1985). "Left ventricular size and function in body builders using anabolic steroids". Medicine and science in sports and exercise. 17 (6): 701–4. PMID 4079743.
- Yamamoto Y, Moore R, Hess H, Guo G, Gonzalez F, Korach K, Maronpot R, Negishi M (2006). "Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity". J Biol Chem. 281 (24): 16625–31. PMID 16606610.
- Socas L, Zumbado M, Pérez-Luzardo O; et al. (2005). "Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature". British journal of sports medicine. 39 (5): e27. doi:10.1136/bjsm.2004.013599. PMID 15849280.
- Velazquez I, Alter BP (2004). "Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions". Am. J. Hematol. 77 (3): 257–67. doi:10.1002/ajh.20183. PMID 15495253.
- Marcus R, Korenman S. "Estrogens and the human male". Annu Rev Med. 27: 357–70. PMID 779604.
- Hoffman JR, Ratamess NA (June 1, 2006). "Medical Issues Associated with Anabolic Steroid Use: Are they Exaggerated?" (PDF). Journal of Sports Science and Medicine. Retrieved 2007-05-08. Check date values in:
- Meriggiola M, Costantino A, Bremner W, Morselli-Labate A (2002). "Higher testosterone dose impairs sperm suppression induced by a combined androgen-progestin regimen". J. Androl. 23 (5): 684–90. PMID 12185103.
- Matsumoto A (1990). "Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production". J. Clin. Endocrinol. Metab. 70 (1): 282–7. PMID 2104626.
- Alén M, Reinilä M, Vihko R (1985). "Response of serum hormones to androgen administration in power athletes". Medicine and science in sports and exercise. 17 (3): 354–9. PMID 2991700.
- Manikkam M, Crespi E, Doop D; et al. (2004). "Fetal programming: prenatal testosterone excess leads to fetal growth retardation and postnatal catch-up growth in sheep". Endocrinology. 145 (2): 790–8. PMID 14576190.
- Irving L, Wall M, Neumark-Sztainer D, Story M (2002). "Steroid use among adolescents: findings from Project EAT". The Journal of adolescent health : official publication of the Society for Adolescent Medicine. 30 (4): 243–52. PMID 11927236.
- Pereira de Jésus-Tran K, Côté PL, Cantin L, Blanchet J, Labrie F, Breton R (2006). "Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity". Protein Sci. 15 (5): 987–99. doi:10.1110/ps.051905906. PMID 16641486.
- Brodsky I, Balagopal P, Nair K (1996). "Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men--a clinical research center study". J. Clin. Endocrinol. Metab. 81 (10): 3469–75. PMID 8855787.
- Hickson R, Czerwinski S, Falduto M, Young A (1990). "Glucocorticoid antagonism by exercise and androgenic-anabolic steroids". Med Sci Sports Exerc. 22 (3): 331–40. PMID 2199753.
- Singh R, Artaza J, Taylor W, Gonzalez-Cadavid N, Bhasin S (2003). "Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway". Endocrinology. 144 (11): 5081–8. PMID 12960001.
- Lavery DN, McEwan IJ (2005). "Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations". Biochem. J. 391 (Pt 3): 449–64. doi:10.1042/BJ20050872. PMID 16238547.
- Cheskis B (2004). "Regulation of cell signalling cascades by steroid hormones". J. Cell. Biochem. 93 (1): 20–7. PMID 15352158.
- Roselli CE (1998). "The effect of anabolic-androgenic steroids on aromatase activity and androgen receptor binding in the rat preoptic area". Brain Res. 792 (2): 271–6. PMID 9593936.
- Basaria S, Wahlstrom JT, Dobs AS (2001). "Clinical review 138: Anabolic-androgenic steroid therapy in the treatment of chronic diseases". J. Clin. Endocrinol. Metab. 86 (11): 5108–17. PMID 11701661.
- Ranke MB, Bierich JR (1986). "Treatment of growth hormone deficiency". Clinics in endocrinology and metabolism. 15 (3): 495–510. PMID 2429792.
- Grunfeld C, Kotler D, Dobs A, Glesby M, Bhasin S (2006). "Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study". J. Acquir. Immune Defic. Syndr. 41 (3): 304–14. PMID 16540931.
- Berger JR, Pall L, Hall CD, Simpson DM, Berry PS, Dudley R (1996). "Oxandrolone in AIDS-wasting myopathy". AIDS. 10 (14): 1657–62. PMID 8970686.
- Arslanian S, Suprasongsin C (1997). "Testosterone treatment in adolescents with delayed puberty: changes in body composition, protein, fat, and glucose metabolism". J. Clin. Endocrinol. Metab. 82 (10): 3213–20. PMID 9329341.
- Matsumoto A (1990). "Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production". J. Clin. Endocrinol. Metab. 70 (1): 282–7. PMID 2104626.
- Aribarg A, Sukcharoen N, Chanprasit Y, Ngeamvijawat J, Kriangsinyos R (1996). "Suppression of spermatogenesis by testosterone enanthate in Thai men". Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 79 (10): 624–9. PMID 8996996.
- Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG (2001). "Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels". J. Gerontol. A Biol. Sci. Med. Sci. 56 (5): M266–72. PMID 11320105.
- Baum NH, Crespi CA (2007). "Testosterone replacement in elderly men". Geriatrics. 62 (9): 14–8. PMID 17824721.
- Francis RM (2001). "Androgen replacement in aging men". Calcif. Tissue Int. 69 (4): 235–8. PMID 11730258.
- Nair KS, Rizza RA, O'Brien P; et al. (2006). "DHEA in elderly women and DHEA or testosterone in elderly men". N. Engl. J. Med. 355 (16): 1647–59. doi:10.1056/NEJMoa054629. PMID 17050889.
- Shah K, Montoya C, Persons R (2007). "Do testosterone injections increase libido for elderly hypogonadal patients?". The Journal of family practice. 56 (4): 301–5. PMID 17403329.
- Yassin A, Saad F (2007). "Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only". The journal of sexual medicine. 4 (2): 497–501. PMID 17367445.
- Arver S, Dobs A, Meikle A; et al. (1997). "Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men". Clin. Endocrinol. (Oxf). 47 (6): 727–37. PMID 9497881.
- Nieschlag E, Büchter D, Von Eckardstein S; et al. (1999). "Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men". Clin. Endocrinol. (Oxf). 51 (6): 757–63. PMID 10619981.
- Moore E, Wisniewski A, Dobs A (2003). "Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects". J. Clin. Endocrinol. Metab. 88 (8): 3467–73. PMID 12915619.
- Yesalis CE, Kennedy NJ, Kopstein AN, Bahrke MS (1993). "Anabolic-androgenic steroid use in the United States". JAMA. 270 (10): 1217–21. PMID 8355384.
- Andrew, Parkinson (2006). "Anabolic-Androgenic Steroids: A Survey of 500 Users". Medicine & Science in Sports & Exercise. American College of Sports Medicine. 38 (4): 644–651. PMID 16679978. Retrieved 2007-04-24. Unknown parameter
- McCabe SE, Brower KJ, West BT, Nelson TF, Wechsler H (2007). "Trends in non-medical use of anabolic steroids by U.S. college students: Results from four national surveys". Drug and alcohol dependence. 90 (2–3): 243–51. doi:10.1016/j.drugalcdep.2007.04.004. PMID 17512138.
- Copeland J, Peters R, Dillon P (1998). "A study of 100 anabolic-androgenic steroid users". Med. J. Aust. 168 (6): 311–2. PMID 9549549.
- Eastley, Tony (January 18, 2006). "Steroid study debunks user stereotypes". abc.net.au. Retrieved 2007-04-24. Check date values in:
- Pope HG, Kanayama G, Ionescu-Pioggia M, Hudson JI (2004). "Anabolic steroid users' attitudes towards physicians". Addiction. 99 (9): 1189–94. doi:10.1111/j.1360-0443.2004.00781.x. PMID 15317640.
- Kanayama G, Barry S, Hudson JI, Pope HG (2006). "Body image and attitudes toward male roles in anabolic-androgenic steroid users". The American journal of psychiatry. 163 (4): 697–703. doi:10.1176/appi.ajp.163.4.697. PMID 16585446.
- Hickson R, Czerwinski S, Falduto M, Young A (1990). "Glucocorticoid antagonism by exercise and androgenic-anabolic steroids". Medicine and science in sports and exercise. 22 (3): 331–40. PMID 2199753.
- Mutzebaugh C (1998). "Does the choice of alpha-AAS really make a difference?". HIV Hotline. 8 (5–6): 10–1. PMID 11366379.
- Kokkinos P, Narayan P, Colleran J; et al. (1995). "Effects of regular exercise on blood pressure and left ventricular hypertrophy in African-American men with severe hypertension". N. Engl. J. Med. 333 (22): 1462–7. PMID 7477146.
- Medraś M, Tworowska U (2001). "[Treatment strategies of withdrawal from long-term use of anabolic-androgenic steroids]". Pol Merkur Lekarski. 11 (66): 535–8. PMID 11899857.
- Dony J, Smals A, Rolland R, Fauser B, Thomas C. "Effect of lower versus higher doses of tamoxifen on pituitary-gonadal function and sperm indices in oligozoospermic men". Andrologia. 17 (4): 369–78. PMID 3931502.
- Plourde P, Reiter E, Jou H; et al. (2004). "Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial". J. Clin. Endocrinol. Metab. 89 (9): 4428–33. PMID 15356042.
- Kaufman K, Olsen E, Whiting D; et al. (1998). "Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group". J Am Acad Dermatol. 39 (4 Pt 1): 578–89. PMID 9777765.
- Frost, Norman. "Steroid Hysteria: Unpacking the Claims". American Medical Association. Retrieved 2007-09-14.
- Bhasin S, Storer T, Berman N; et al. (1996). "The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men". N. Engl. J. Med. 335 (1): 1–7. PMID 8637535.
- Schroeder E, Vallejo A, Zheng L; et al. (2005). "Six-week improvements in muscle mass and strength during androgen therapy in older men". J. Gerontol. A Biol. Sci. Med. Sci. 60 (12): 1586–92. PMID 16424293.
- Grunfeld C, Kotler D, Dobs A, Glesby M, Bhasin S (2006). "Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study". J. Acquir. Immune Defic. Syndr. 41 (3): 304&ndash, 14. PMID 16540931.
- Bhasin S, Woodhouse L, Casaburi R; et al. (2001). "Testosterone dose-response relationships in healthy young men". Am. J. Physiol. Endocrinol. Metab. 281 (6): E1172–81. PMID 11701431.
- Kotler, Steven (July 2005). "Sympathy for the Devil". LA Weekly. Retrieved 2007-04-24.
- Puma, Mike. "Not the size of the dog in the fight". ESPN.com. ESPN. Retrieved 2007-07-05.
- Maravelias C, Dona A, Stefanidou M, Spiliopoulou C (2005). "Adverse effects of anabolic steroids in athletes. A constant threat". Toxicol. Lett. 158 (3): 167–75. doi:10.1016/j.toxlet.2005.06.005. PMID 16005168.
- Woolston, Chris (2004-03-24). "Ills & Conditions". CONSUMER HEALTH INTERACTIVE. Retrieved 2007-06-28. Check date values in:
- "Real Sports, Lyle Alzado". elitefitness.com. Retrieved 2007-04-24.
- "Teens & Steroids: A Dangerous Mix". CBS. CBS Broadcasting Inc. 2004-06-03. Retrieved 2007-06-27. Check date values in:
- Darkes, PhD, Jack (2005 July). "Anabolic-Androgenic Steroids and Suicide, A Brief Review of the Evidence". MESO-Rx. Retrieved 2007-04-24. Check date values in:
- Uzych L (1992). "Anabolic-androgenic steroids and psychiatric-related effects: a review". Canadian journal of psychiatry. Revue canadienne de psychiatrie. 37 (1): 23–8. PMID 1551042.
- Pope H, Katz D (1988). "Affective and psychotic symptoms associated with anabolic steroid use". The American journal of psychiatry. 145 (4): 487–90. PMID 3279830.
- Fudala P, Weinrieb R, Calarco J, Kampman K, Boardman C (2003). "An evaluation of anabolic-androgenic steroid abusers over a period of 1 year: seven case studies". Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. 15 (2): 121–30. PMID 12938869.
- Bahrke MS, Yesalis CE, Wright JE (1996). "Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids. An update". Sports medicine (Auckland, N.Z.). 22 (6): 367–90. PMID 8969015.
- Dalby JT (1992). "Brief anabolic steroid use and sustatined behavioral reaction". American Journal of Psychiatry. 149 (3): 271-272+1616. PMID 1734751.
- Pope, Harrison G. (2000 February). "Effects of Supraphysiologic Doses of Testosterone on Mood and Aggression in Normal Men". Med Sci Sports Exerc. Arch Gen Psychiatry. 57 (2): 133–140. PMID 10665615. Retrieved 2007-04-24. Unknown parameter
|coauthors=ignored (help); Check date values in:
- Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS (2006). "Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlate to the severity of abuse". Eur. Psychiatry. 21 (8): 551–62. doi:10.1016/j.eurpsy.2005.09.001. PMID 16356691.
- Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS, Toli PN (2006). "Psychiatric and hostility factors related to use of anabolic steroids in monozygotic twins". Eur. Psychiatry. 21 (8): 563–9. doi:10.1016/j.eurpsy.2005.11.002. PMID 16529916.
- Perry PJ, Kutscher EC, Lund BC, Yates WR, Holman TL, Demers L (2003). "Measures of aggression and mood changes in male weightlifters with and without androgenic anabolic steroid use". J. Forensic Sci. 48 (3): 646–51. PMID 12762541.
- Tricker R, Casaburi R, Storer T; et al. (1996). "The effects of supraphysiological doses of testosterone on angry behavior in healthy eugonadal men--a clinical research center study". J. Clin. Endocrinol. Metab. 81 (10): 3754–8. PMID 8855834.
- O'Connor D, Archer J, Hair W, Wu F (2002). "Exogenous testosterone, aggression, and mood in eugonadal and hypogonadal men". Physiol. Behav. 75 (4): 557–66. PMID 12062320.
- "Critics Slam Schwarzenegger on Steroids". Associated press. Retrieved 2007-05-11.
- Guttman, Monika (1997). "Schwarzenegger gets new role: patient at University Hospital". University of Southern California. Retrieved 2007-04-24.
- Collins, Rick (December 1, 2002). Legal Muscle: Anabolics in America. Legal Muscle Publishing Inc. p. 430. ISBN 0-9726384-0-7. Check date values in:
- D. Kochakian, Charles. Anabolic Steroids in Sport and Exercise. Human Kinetics.
- Daniels, R. C. (February 1, 2003). The Anabolic Steroid Handbook. Richard C Daniels. p. 80. ISBN 0-9548227-0-6. Unknown parameter
|coauthors=ignored (help); Check date values in:
- Gallaway, Steve (January 15, 1997). The Steroid Bible. Belle Intl; 3rd Sprl edition. p. 125. ISBN 1-890342-00-9. Check date values in:
- Llewellyn, William (January 28, 2007). ANABOLICS 2007 : Anabolic Steroid Reference Manual (6th Ed.). Body of Science. p. 988. ISBN 978-0967930466. Check date values in:
- Roberts, Anthony (January 2006). Anabolic Steroids: Ultimate Research Guide. Anabolic Books, LLC. p. 394. ISBN 1-59975-100-3. Unknown parameter
- Roberts, Anthony (May 2006). Beyond Steroids. EF Publishing Inc. p. 250.
- Taylor, William N (January 1, 2002). Anabolic Steroids and the Athlete. McFarland & Company. p. 373. ISBN 0-7864-1128-7. Check date values in:
- Yesalis, Charles E. (July 2000). Anabolic Steroids in Sport and Exercise. Human Kinetics Publishers; 2nd edition. p. 493. ISBN 0-88011-786-9.
- Steroids news page – Alcohol and Drugs History Society
- Association against Steroid Abuse
- Mesomorphosis steroid articles – Articles on Steroids
de:Anabole Steroide gl:Esteroide anabólico it:Anabolizzante he:סטרואידים אנאבוליים lt:Anaboliniai steroidai nl:Anabole steroïde no:Anabole steroider sr:Анаболички стероиди fi:Anabolinen steroidi sv:Anabola steroider uk:Анаболічні стероїди